Professional
Added to YB: 2024-03-25
Pitch date: 2023-12-31
NTRA [bullish]
Natera, Inc.
+276.05%
current return
Author Info
No bio for this author
Company Info
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Market Cap
$28.2B
Pitch Price
$61.68
Price Target
N/A
Dividend
N/A
EV/EBITDA
-91.38
P/E
-89.19
EV/Sales
12.92
Sector
Biotechnology
Category
growth
Alger Mid Cap Growth Fund Portfolio Holding: Natera, Inc.
NTRA: Specialty lab for genetic testing in reproductive health, oncology & transplants. Q3 beat on revenue, Signatera volume & margins drove guidance raise. Proprietary cell-free DNA platform powers prenatal (NIPT), cancer recurrence (Signatera) & organ rejection (Prospera) tests.
Read full article (1 min)